Home › Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines
 

Keywords :   


Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines

2013-06-12 14:00:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Associations (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA (sitagliptin). Language:  English Contact HTML:  MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: other profile review safety

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07M13 Graphics invests in Landa digital press
02.07ABG helps Nordvalls increase productivity
02.07Tesla sales rise sharply after slump
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Forecast Discussion Number 16
02.07Fedrigoni teams with Progetto Quid
02.07Hurricane Beryl Forecast Advisory Number 16
02.07Hurricane Beryl Public Advisory Number 16
More »